Making NGS Work for Analytical Development and QC

For years, next-generation sequencing (NGS) has been used to generate data for research and discovery. Today, its role is expanding into a GxP-ready technology that supports analytical development, manufacturing, and quality control (QC), helping characterize biotherapeutic products and ensure control throughout their lifecycle. 

The use of NGS in these settings is increasingly supported by regulatory agencies, which recognize it as a robust, broad, and sensitive approach for addressing the complexity of modern modalities.¹ By consolidating information that would otherwise require multiple assays, NGS enables a more comprehensive end-to-end workflow. For Analytical R&D teams, developing NGS assays is becoming essential to enable rapid, sensitive, and specific quality assessment while meeting evolving regulatory expectations. However, realizing this potential requires more than sequencing capacity alone; it depends on translating complex, high-throughput data into actionable analytical insights. Many teams still rely on fragmented bioinformatics pipelines or external services to process, analyze, and interpret NGS data, making the process time- and resource-intensive, difficult to scale, and challenging to transfer into manufacturing and QC. 

Genedata Selector^® helps overcome this bottleneck by enabling fast, in-house, and user-friendly NGS analysis and interpretation of both short- and long-read sequencing data, turning outputs into confident quality decisions at scale. 

Moving From Flexible Method Design to Standardized QC

The role of analytical development is to design, validate, and apply methods that evaluate the quality of a drug product These methods are used to characterize key product attributes such as identity, integrity, purity, potency, safety, biosafety, and other critical quality attributes (CQAs)^2,3 This differs from QC workflows, where the focus shifts from flexible method exploration and optimization to standardized, validated, and routine execution. To transfer an assay into regulated testing, workflows must be well documented, consistent, and robust.

Discover NGS Use for QC & CQAs

Expanding the Role of NGS in Analytical Development

NGS is increasingly being applied to modern biotherapeutics and other complex therapeutic modalities, including cell and gene therapies, viral vectors, mRNA therapeutics, and engineered cell lines. This is because it provides a holistic and high-resolution view of a therapeutic substance or product. Rather than relying on multiple separate assays to assess individual product attributes, NGS can serve as a Multi-Attribute Method, supporting the assessment of the product identity, sequence integrity, genetic stability, biosafety, and adventitious agent detection within a single assay.

Explore NGS as a Multi-Attribute Method 

Applied across multiple analytical use cases, NGS helps teams generate deeper molecular insights earlier in development and support decisions around characterization, comparability, and control strategy.  NGS is also increasingly recognized in regulatory frameworks as a scalable, sensitive, and transferable methodology for safety.⁴ The revised ICH Q5A(R2) guideline explicitly recognizes NGS as a complementary technology for viral safety evaluation and virus detection.^5,6 NGS can also be used in a broader biopharmaceutical quality assessment in GMP environments, provided assays are implemented as fully validated, traceable, fit-for-purpose workflows spanning sample preparation, sequencing, bioinformatics, data analysis, and reporting.⁷ Because NGS generates large volumes of electronic data, compliance with FDA 21 CFR Part 11 is critical.⁸ 

Explore Current NGS Regulations

Turning NGS Data Analysis into a Scalable, Accessible Workflow

Implementing NGS in analytical development is not simply a matter of adding sequencing capacity; it requires both extensive wet-lab data generation and a robust bioinformatic analysis pipeline. Once sequencing data is generated, teams must manage large, complex datasets and establish reliable and replicable methods to ingest, analyze, interpret, and report findings. Without platform infrastructure, NGS-based approaches often rely on disconnected tools, siloed data, fragmented scripts, and repetitive manual handling steps that depend on advanced bioinformatics expertise or outsourced support. This can slow timelines, introduce inconsistencies, and limit traceability, making advanced methodologies difficult to standardize, scale, and transfer into QC. In addition, regulated, fit-to-purpose NGS methods must deliver reproducible results across sites, instruments, teams, and operators while meeting expectations for sensitivity, specificity, robustness, and limit of detection. Therefore, beyond assay fitness for purpose, organizations must address end-to-end workflow validation, including bioinformatics pipeline control, data integrity, and audit trails, to ensure regulatory readiness.⁵ Successful implementation requires not only strong technical performance but also efficient technology transfer and coordination across analytical development, bioinformatics, QA, QC, IT, regulatory affairs, and manufacturing.

Making NGS Adoption in Analytical Development Possible

To address these challenges, analytical development teams need a scalable software environment that supports end-to-end, in-house NGS data analysis; standardizes assay execution; manages samples and data; and preserves traceability from sample data registration through reporting. Genedata Selector provides these capabilities within a single enterprise platform, combining out-of-the-box, standardized NGS workflows with the flexibility required for complex analytical development use cases (e.g., CQA characterization, or genetic stability assessment). By automating data-related tasks, Genedata Selector reduces reliance on scarce bioinformatics resources, broadens access to NGS across the organization, and supports GMP-ready, consistent, and traceable operations.

Learn About In-House NGS

Benefits for Analytical Experts

For NGS to move successfully from analytical development into QC and manufacturing, compliance and GMP readiness must be built in from the start. Assay design, method selection, workflow execution, and the data generated during development need to support reproducibility, traceability, and transferability across environments. 

Incorporating Computerized System Validation (CSV), standardized workflows, controlled execution, audit trails, data integrity controls, and comprehensive, inspection-ready documentation during analytical development can reduce rework during validation and facilitate technology transfer across teams, sites, and operators. With GMP-compliant NGS software, organizations can meet regulatory expectations from day one, building workflows that are not only scientifically robust but also ready to scale into QC and manufacturing.

Learn How to Validate NGS in GMP

Building Scalable, In-House NGS Capabilities

Establishing innovative, yet validation-ready, NGS methods to improve the quality of products is one of the main focuses of Analytical R&D Groups. Therefore, the ability to easily analyze and interpret sequencing data for reliable, yet faster decision-making is a strategic capability. Genedata Selector helps organizations reduce the cost and delays associated with fragmented tools, repeated manual handovers, and outsourced analysis by enabling scalable NGS workflows within a standardized, traceable, and user-friendly in-house environment. Consequently, scientific teams not only generate decision-ready results faster and use internal expertise more effectively but also build a repeatable framework that prepares for QC and manufacturing use in the future. In this way, Genedata Selector supports greater operational performance and more sustainable, enterprise-wise NGS adoption. 

See Genedata Selector in Action